Providing Clinical Insights Into Myeloid Malignancies

December 09, 2019

The integration of next-generation sequencing (NGS) into the diagnostic process for hematologic malignancies has greatly improved the accuracy and speed of confirming or refining the diagnosis and following minimal residual disease. Optimization of gene selection and assay development, together with skilled interpretation, are key factors in the execution of a clinically relevant NGS test for hematologic malignancies.

In this webinar, we will describe Quest’s LeukoVantage assay, an NGS test designed specifically for detecting clinically relevant variants in myeloid malignancies, and its partnership with N-of-One, a QIAGEN company, for expert interpretation. LeukoVantage covers the most important genes for myeloid diagnostics, with focused panels that allow rapid turnaround. N-of-One’s team of experienced PhDs provides expert, evidence-based annotation incorporating WHO, NCCN, and ELN guidelines, with clinically relevant information vetted by oncologists. N-of-One reports include diagnostic and prognostic information, therapeutic options, and clinical trials based on the unique combination of genomic alterations detected in each case. These reports are then reviewed, modified, and signed out by Quest pathologists.

Interested in learning more?

Click here


Sheryl Krevsky Elkin, PhD, Chief Scientific Officer, N-of-One, a QIAGEN company

Frederick K. Racke, MD, PhD, Medical Director Hematology/Oncology and Coagulation, Nichols Institute San Juan Capistrano, CA

Related videos


Get expert variant classification services tailored to your onco-panel

266 views December 09, 2021

As next-generation DNA sequencing technology continues to evolve and become...


Accurate and efficient interpretation with QCI Precision Insights

573 views March 20, 2020

As next-generation DNA sequencing technology continues to evolve and become...